Evidence map›Paper›PMID 31929594›Full record

ArticlePloS one2020

Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease.

Victoria Schiffer, Estibaliz Santiago-Mujika, Stefanie Flunkert, Staffan Schmidt, Martina Farcher, Tina Loeffler, Irene Schilcher, Maria Posch, Joerg Neddens, Ying Sun and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Victoria SchifferQPS Austria GmbH, Neuropharmacology, Grambach, Austria.
Estibaliz Santiago-MujikaQPS Austria GmbH, Neuropharmacology, Grambach, Austria.
Stefanie FlunkertQPS Austria GmbH, Neuropharmacology, Grambach, Austria.ORCID 0000-0003-3806-3907
Staffan SchmidtPronexus Analytical AB, Bromma, Sweden.
Martina FarcherQPS Austria GmbH, Neuropharmacology, Grambach, Austria.
Tina LoefflerQPS Austria GmbH, Neuropharmacology, Grambach, Austria.
Irene SchilcherQPS Austria GmbH, Neuropharmacology, Grambach, Austria.
Maria PoschQPS Austria GmbH, Neuropharmacology, Grambach, Austria.
Joerg NeddensQPS Austria GmbH, Neuropharmacology, Grambach, Austria.
Ying SunDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
Jan KehrPronexus Analytical AB, Bromma, Sweden.
Birgit Hutter-PaierQPS Austria GmbH, Neuropharmacology, Grambach, Austria.
QPS (Austria) · ATCincinnati Children's Hospital Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gaucher disease is caused by a deficiency in glucocerebrosidase that can result in non-neuronal as well as neuronal symptoms. Common visceral symptoms are an increased organ size, specifically of the spleen, and glucosylceramide as well as glucosylsphingosine substrate accumulations as a direct result of the glucocerebrosidase deficiency. Neuronal symptoms include motor deficits and strong alterations in the cerebellum. To evaluate the effect of new compounds for the treatment of this devastating disease, animal models are needed that closely mimic the human phenotype. The 4L/PS-NA mouse as model of Gaucher disease is shown to present reduced glucocerebrosidase activity similar to human cases but an in-depth characterization of the model was still not performed. We therefore analyzed 4L/PS-NA mice for visceral alterations, motor deficits and also neuronal changes like glucocerebrosidase activity, substrate levels and neuroinflammation. A special focus was set at pathological changes of the cerebellum. Our results show that 4L/PS-NA mice have strongly enlarged visceral organs that are infiltrated by enlarged leukocytes and macrophages. Furthermore, animals present strong motor deficits that are accompanied by increased glucosylceramide and glucosylsphingosine levels in the brain, astrocytosis and activated microglia in the cortex and hippocampus as well as reduced calbindin levels in the cerebellum. The latter was directly related to a strong Purkinje cell loss. Our results thus provide a detailed characterization of the 4L/PS-NA mouse model over age showing the translational value of the model and validating its usefulness for preclinical efficiency studies to evaluate new compounds against Gaucher disease.

Indexed as

Disease Models, AnimalPhenotypeAnimalsCerebellumFemaleGaucher DiseaseGlucosylceramidaseLeukocytesLiverLungMaleMiceMice, Inbred C57BLMovementMutationNeuronsGlucosylceramidase

Identifiers

PMID31929594
PMCPMC6957154
OpenAlexW3000423820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.